A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

Trial Details

NCT ID
NCT03423628
Phase
PHASE1
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Radiation Therapy
  • AZD1390
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

  • Provision of formalin-fixed paraffin embedded tissue sample from primary or metastatic disease
  • Karnofsky Performance Score of ≥60.
  • Additional Inclusion Criteria Specific for Arm A and Japan:
  • Histologically proven diagnosis of GBM. Patients who have had RT for low-grade glioma (LGG) or grade 3 glioma and have subsequently relapsed to his…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →